ZA200701484B - Combination therapy using transferrin fusion proteins comprising GLP-1 - Google Patents
Combination therapy using transferrin fusion proteins comprising GLP-1Info
- Publication number
- ZA200701484B ZA200701484B ZA200701484A ZA200701484A ZA200701484B ZA 200701484 B ZA200701484 B ZA 200701484B ZA 200701484 A ZA200701484 A ZA 200701484A ZA 200701484 A ZA200701484 A ZA 200701484A ZA 200701484 B ZA200701484 B ZA 200701484B
- Authority
- ZA
- South Africa
- Prior art keywords
- glp
- fusion proteins
- combination therapy
- transferrin fusion
- transferrin
- Prior art date
Links
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 102000004338 Transferrin Human genes 0.000 title 1
- 108090000901 Transferrin Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 239000012581 transferrin Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59803104P | 2004-08-03 | 2004-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200701484B true ZA200701484B (en) | 2008-07-30 |
Family
ID=35839920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200701484A ZA200701484B (en) | 2004-08-03 | 2005-08-03 | Combination therapy using transferrin fusion proteins comprising GLP-1 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1814599A4 (en) |
| JP (1) | JP2008509153A (en) |
| KR (1) | KR20070085224A (en) |
| CN (1) | CN101035568A (en) |
| AP (1) | AP2007003920A0 (en) |
| AU (1) | AU2005271403A1 (en) |
| BR (1) | BRPI0514115A (en) |
| CA (1) | CA2575756A1 (en) |
| CR (1) | CR8954A (en) |
| EA (1) | EA200700391A1 (en) |
| GB (1) | GB2431583A (en) |
| IL (1) | IL181108A0 (en) |
| MA (1) | MA28843B1 (en) |
| MX (1) | MX2007001424A (en) |
| NO (1) | NO20071018L (en) |
| RU (1) | RU2007107808A (en) |
| TN (1) | TNSN07039A1 (en) |
| WO (1) | WO2006017688A2 (en) |
| ZA (1) | ZA200701484B (en) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| JP4681231B2 (en) | 2002-03-20 | 2011-05-11 | マンカインド コーポレイション | Inhaler |
| BRPI0514263B8 (en) | 2004-08-20 | 2021-05-25 | Mannkind Corp | method for the synthesis of n-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine n-protected |
| KR101306384B1 (en) | 2004-08-23 | 2013-09-09 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
| WO2006096515A2 (en) * | 2005-03-04 | 2006-09-14 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| EP1928423B1 (en) | 2005-09-14 | 2015-12-09 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| WO2007098500A2 (en) | 2006-02-22 | 2007-08-30 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| KR101193722B1 (en) * | 2006-07-24 | 2013-01-11 | 바이오렉시스 파마슈티칼 코포레이션 | Exendin fusion proteins |
| WO2008033395A2 (en) * | 2006-09-14 | 2008-03-20 | Biorexis Pharmaceutical Corporation | Melanocortin and transferrin fusion proteins |
| US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| CA2982550C (en) | 2008-06-13 | 2020-08-25 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CN102065942B (en) | 2008-06-20 | 2013-12-11 | 曼金德公司 | An interactive apparatus and method for real-time profiling of inhalation efforts |
| TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| PL2405963T3 (en) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Apparatus, system and method for measuring resistance of an inhaler |
| ES2943333T3 (en) | 2009-06-12 | 2023-06-12 | Mannkind Corp | Diketopiperazine microparticles with defined surface areas |
| EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
| AU2011271097B2 (en) | 2010-06-21 | 2014-11-27 | Mannkind Corporation | Dry powder drug delivery system and methods |
| JP5688718B2 (en) | 2010-08-27 | 2015-03-25 | 国立大学法人 宮崎大学 | Hemokinin-1 receptor and hemokinin-1-derived peptide |
| CN103826988B (en) | 2011-04-01 | 2016-03-09 | 曼金德公司 | For the blister package of pharmaceutical kit |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| RU2477726C1 (en) * | 2011-10-18 | 2013-03-20 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | Substituted phenoxyacetic acids, their esters and amides containing 2,6-dioxo-2,3,6,7-tetrahydro-1h-pyrin-8-yl fragments - a2a adenosine receptor antagonists and use thereof |
| JP6018640B2 (en) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | Analgesic composition effective for alleviating pain, and dry powder and dry powder drug delivery system comprising the composition |
| CN103160565A (en) * | 2011-12-09 | 2013-06-19 | 彩虹天健康科技研究(北京)有限责任公司 | Research for influence on endocytosis of cell transferrins of UNC-51 kinase |
| CA2871468C (en) * | 2012-04-23 | 2021-09-21 | Nrl Pharma, Inc. | Lactoferrin fusion protein and method for preparation thereof |
| US9802012B2 (en) | 2012-07-12 | 2017-10-31 | Mannkind Corporation | Dry powder drug delivery system and methods |
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| PL2934567T3 (en) | 2012-12-21 | 2018-10-31 | Sanofi | Exendin-4 derivatives as dual glp1/gip- or trigonal glp1/gip/glucagon agonists |
| KR102391750B1 (en) | 2013-03-15 | 2022-04-28 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
| CN103275177B (en) * | 2013-06-24 | 2015-08-12 | 南京财经大学 | There is the little peptide of feritin and ACE dual restraining activities, its preparation method and application |
| CN105451716A (en) | 2013-07-18 | 2016-03-30 | 曼金德公司 | Heat-stable dry powder pharmaceutical compositions and methods |
| US11446127B2 (en) | 2013-08-05 | 2022-09-20 | Mannkind Corporation | Insufflation apparatus and methods |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609799A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/GIP receptor agonists |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| CN106397606B (en) * | 2015-01-28 | 2020-11-10 | 中国科学院天津工业生物技术研究所 | Application of polypeptide compound as SST drug carrier, method and fusion protein compound thereof |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| AR105284A1 (en) | 2015-07-10 | 2017-09-20 | Sanofi Sa | DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS |
| CA3080406A1 (en) | 2016-10-28 | 2018-05-03 | Nrl Pharma, Inc. | Lactoferrin/albumin fusion protein and production method thereof |
| US11459368B2 (en) | 2017-07-14 | 2022-10-04 | Livactus, Inc. | Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance |
| WO2019243502A1 (en) * | 2018-06-21 | 2019-12-26 | Novo Nordisk A/S | Novel compounds for treatment of obesity |
| CN110218259B (en) * | 2019-06-24 | 2022-09-16 | 王跃驹 | Application of fusion protein of glucagon-like peptide-1 short peptide and transferrin produced by plants in preparing oral hypoglycemic capsules |
| CN112661862B (en) * | 2020-12-25 | 2023-03-31 | 深圳大学 | Fusion protein and preparation method and application thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US7285526B2 (en) * | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| DK1317479T3 (en) * | 2000-09-06 | 2009-11-23 | Aventis Pharma Sa | Methods and Compositions for Diseases Associated with Amyloidosis |
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| ATE409466T1 (en) * | 2002-01-11 | 2008-10-15 | Novo Nordisk As | METHOD AND COMPOSITION FOR TREATING DIABETES, HYPERTENSION, CHRONIC HEART FAILURE AND CONDITIONS ASSOCIATED WITH FLUID RETENTION |
| AU2003270009A1 (en) * | 2002-08-30 | 2004-03-19 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
| EP1545595B1 (en) * | 2002-08-30 | 2010-07-07 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
-
2005
- 2005-08-03 RU RU2007107808/14A patent/RU2007107808A/en not_active Application Discontinuation
- 2005-08-03 CN CNA2005800336740A patent/CN101035568A/en active Pending
- 2005-08-03 KR KR1020077005257A patent/KR20070085224A/en not_active Application Discontinuation
- 2005-08-03 WO PCT/US2005/027800 patent/WO2006017688A2/en active Application Filing
- 2005-08-03 CA CA002575756A patent/CA2575756A1/en not_active Abandoned
- 2005-08-03 JP JP2007525008A patent/JP2008509153A/en not_active Withdrawn
- 2005-08-03 EP EP05782173A patent/EP1814599A4/en not_active Withdrawn
- 2005-08-03 AP AP2007003920A patent/AP2007003920A0/en unknown
- 2005-08-03 AU AU2005271403A patent/AU2005271403A1/en not_active Abandoned
- 2005-08-03 MX MX2007001424A patent/MX2007001424A/en not_active Application Discontinuation
- 2005-08-03 ZA ZA200701484A patent/ZA200701484B/en unknown
- 2005-08-03 EA EA200700391A patent/EA200700391A1/en unknown
- 2005-08-03 BR BRPI0514115-0A patent/BRPI0514115A/en not_active IP Right Cessation
-
2007
- 2007-02-01 IL IL181108A patent/IL181108A0/en unknown
- 2007-02-02 TN TNP2007000039A patent/TNSN07039A1/en unknown
- 2007-02-22 NO NO20071018A patent/NO20071018L/en not_active Application Discontinuation
- 2007-02-26 GB GB0703685A patent/GB2431583A/en not_active Withdrawn
- 2007-03-02 CR CR8954A patent/CR8954A/en not_active Application Discontinuation
- 2007-03-02 MA MA29727A patent/MA28843B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070085224A (en) | 2007-08-27 |
| MX2007001424A (en) | 2008-03-13 |
| WO2006017688A3 (en) | 2006-08-03 |
| AU2005271403A1 (en) | 2006-02-16 |
| CN101035568A (en) | 2007-09-12 |
| IL181108A0 (en) | 2007-07-04 |
| EP1814599A4 (en) | 2008-12-17 |
| GB0703685D0 (en) | 2007-04-04 |
| BRPI0514115A (en) | 2008-05-27 |
| TNSN07039A1 (en) | 2008-06-02 |
| CR8954A (en) | 2007-10-02 |
| EA200700391A1 (en) | 2007-10-26 |
| EP1814599A2 (en) | 2007-08-08 |
| WO2006017688A2 (en) | 2006-02-16 |
| RU2007107808A (en) | 2008-09-10 |
| JP2008509153A (en) | 2008-03-27 |
| AP2007003920A0 (en) | 2007-02-28 |
| GB2431583A (en) | 2007-05-02 |
| MA28843B1 (en) | 2007-09-03 |
| NO20071018L (en) | 2007-04-11 |
| CA2575756A1 (en) | 2006-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2007003920A0 (en) | Combination therapy using transferrin fusion proteins comprising glp-1 | |
| HUS1500024I1 (en) | Glp-1 analog fusion proteins | |
| PL1830872T3 (en) | Fusion proteins | |
| GB0426397D0 (en) | Fusion proteins | |
| IL176894A0 (en) | Albumin fusion proteins | |
| EP1720996A4 (en) | Fusion proteins containing recombinant cytotoxic rnases | |
| EP1611093A4 (en) | Modified transferrin fusion proteins | |
| EP1858546A4 (en) | Modified transferrin fusion proteins | |
| IL206518A0 (en) | HETERODIMERIC FOLLICLE STIMULATING HORMONE - Fc (FSH-Fc) FUSION PROTEINS | |
| IL189246A0 (en) | Albumin fusion proteins | |
| EP1934372A4 (en) | Ssb - polymerase fusion proteins | |
| ZA200801224B (en) | Albumin fusion proteins | |
| EP1773385A4 (en) | SKIN IMMUNIZATION USING LT-STa FUSION PROTEINS | |
| EP1670428A4 (en) | G-csf transferrin fusion proteins | |
| GB0423974D0 (en) | Proteins | |
| IL178517A0 (en) | Therapeutic peptides | |
| GB0402660D0 (en) | Heterologous protein expression | |
| GB0402904D0 (en) | Polypeptide | |
| GB0426399D0 (en) | Fusion proteins | |
| PT1833847E (en) | Igf-1 fusion polypeptides and therapeutic uses thereof | |
| SI1833847T1 (en) | Igf-1 fusion polypeptides and therapeutic uses thereof | |
| GB0422110D0 (en) | Recombinant proteins | |
| GB0408390D0 (en) | Therapeutic peptides | |
| HK1082770A1 (en) | Supter-antigen fusion proteins and the use thereof | |
| GB0406408D0 (en) | Targeting polypeptide |